These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27372405)

  • 1. Synergistic inhibition of sunitinib and ethaselen against human colorectal cancer cells proliferation.
    Zheng X; Zhang Y; Zhang L; Xu W; Ma W; Sun R; Zeng H
    Biomed Pharmacother; 2016 Oct; 83():212-220. PubMed ID: 27372405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergism between thioredoxin reductase inhibitor ethaselen and sodium selenite in inhibiting proliferation and inducing death of human non-small cell lung cancer cells.
    Zheng X; Xu W; Sun R; Yin H; Dong C; Zeng H
    Chem Biol Interact; 2017 Sep; 275():74-85. PubMed ID: 28757135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitory effect of a novel organoselenium compound BBSKE on the tongue cancer Tca8113 in vitro and in vivo.
    Xing F; Li S; Ge X; Wang C; Zeng H; Li D; Dong L
    Oral Oncol; 2008 Oct; 44(10):963-9. PubMed ID: 18282784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest.
    Fu JN; Li J; Tan Q; Yin HW; Xiong K; Wang TY; Ren XY; Zeng HH
    Invest New Drugs; 2011 Aug; 29(4):627-36. PubMed ID: 20195699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells.
    Peng ZF; Lan LX; Zhao F; Li J; Tan Q; Yin HW; Zeng HH
    J Zhejiang Univ Sci B; 2008 Jan; 9(1):16-21. PubMed ID: 18196608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.
    Zhang H; Wu J; Yuan J; Li H; Zhang Y; Wu W; Chen W; Wang C; Meng S; Chen S; Huo M; He Y; Zhang C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):260. PubMed ID: 34412665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Induction of apoptosis in prostate cancer cell line PC-3 by BBSKE, a novel organoselenium compound, and its effect in vivo].
    Shi CJ; Zeng HH; Li HW; Yang FG; Wu XQ; Yu LZ
    Zhonghua Yi Xue Za Zhi; 2003 Nov; 83(22):1984-8. PubMed ID: 14703435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: possible involvement of nuclear factor-kappaB-dependent pathway.
    Lan L; Zhao F; Wang Y; Zeng H
    Eur J Pharmacol; 2007 Jan; 555(2-3):83-92. PubMed ID: 17116300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antimetastatic effect and underlying mechanisms of thioredoxin reductase inhibitor ethaselen.
    Zheng X; Chen Y; Bai M; Liu Y; Xu B; Sun R; Zeng H
    Free Radic Biol Med; 2019 Feb; 131():7-17. PubMed ID: 30496814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of ethaselen and selenite treatment against A549 human non-small cell lung cancer cells.
    Xu W; Ma WW; Zeng HH
    Asian Pac J Cancer Prev; 2014; 15(17):7129-35. PubMed ID: 25227802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines.
    Zhao F; Yan J; Deng S; Lan L; He F; Kuang B; Zeng H
    Cancer Lett; 2006 May; 236(1):46-53. PubMed ID: 15982805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mechanism of ethaselen in poorly differentiated colorectal RKO cell growth inhibition: Simultaneous regulation of TrxR transcription, expression and enzyme activity.
    Yin H; Li J; Xiong K; Wang L; Wang T; Tan Q; Fu J; Ren X; Zeng H
    Differentiation; 2011 Jan; 81(1):49-56. PubMed ID: 20864247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines.
    Shi C; Yu L; Yang F; Yan J; Zeng H
    Biochem Biophys Res Commun; 2003 Sep; 309(3):578-83. PubMed ID: 12963029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethaselen: a novel organoselenium anticancer agent targeting thioredoxin reductase 1 reverses cisplatin resistance in drug-resistant K562 cells by inducing apoptosis.
    Ye SF; Yang Y; Wu L; Ma WW; Zeng HH
    J Zhejiang Univ Sci B; 2017 May; 18(5):373-382. PubMed ID: 28471109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.
    Wang L; Yang Z; Fu J; Yin H; Xiong K; Tan Q; Jin H; Li J; Wang T; Tang W; Yin J; Cai G; Liu M; Kehr S; Becker K; Zeng H
    Free Radic Biol Med; 2012 Mar; 52(5):898-908. PubMed ID: 22210352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
    Di Desidero T; Fioravanti A; Orlandi P; Canu B; Giannini R; Borrelli N; Man S; Xu P; Fontanini G; Basolo F; Kerbel RS; Francia G; Danesi R; Bocci G
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1465-73. PubMed ID: 23969186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy.
    Wang L; Fu JN; Wang JY; Jin CJ; Ren XY; Tan Q; Li J; Yin HW; Xiong K; Wang TY; Liu XM; Zeng HH
    Anticancer Drugs; 2011 Sep; 22(8):732-40. PubMed ID: 21562407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
    Ping SY; Wu CL; Yu DS
    Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model.
    Ye SF; Li J; Ji SM; Zeng HH; Lu W
    Acta Pharmacol Sin; 2017 Feb; 38(2):223-232. PubMed ID: 27917873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.